115例注射用甲磺酸加贝酯临床应用合理性评价  

Rationality evaluation on the clinical use of gabexate mesilate for injection in 115 inpatients

作　　者：王华光[1] 郑芸颖[1] 王诗卉[1] 杨婧[1] 侯珂露 王颖[1] 崔向丽[1] 刘丽宏[1] WANG Hua-guang;ZHENG Yun-ying;WANG Shi-hui;YANG Jing;HOU Ke-lu;WANG Ying;CUI Xiang-li;LIU Li-hong(Department of Pharmacy,Beijing Chaoyang Hospital Affiliate to Capital University of Medical Sciences,Beijing 100020,China)

机构地区：[1]首都医科大学附属北京朝阳医院药事部,北京100020

出　　处：《中国新药杂志》2019年第1期110-116,共7页Chinese Journal of New Drugs

摘　　要：目的:调查住院患者甲磺酸加贝酯的使用情况,为临床合理用药提供参考。方法:调取我院2017年3月1日—2017年3月31日期间使用甲磺酸加贝酯的全部住院病例115例,收集患者性别、年龄、诊断、药物用法用量、溶媒、疗程及联合用药等数据,采用Microsoft 2011版Excel软件进行统计分析。此外,从上述115例患者中筛选出诊断为胰腺炎者,共入组26例,对其甲磺酸加贝酯不同给药方案进行了初步研究。结果:115例患者中,男女比例接近1∶1,41～60岁使用者居多。无明确用药指征的患者占45. 22%;溶媒选择不正确者仅占2. 61%;溶媒量使用不适宜者占74. 78%;甲磺酸加贝酯用药疗程符合说明书推荐者占93. 91%。甲磺酸加贝酯单药或联合用药或不同给药疗程(小于或大于5 d)对胰腺炎患者的实验室指标、腹痛和住院天数均无明显影响。结论:甲磺酸加贝酯的临床使用仍存在不足之处,在没有足够循证医学证据支持的情况下,不建议甲磺酸加贝酯与同类药物乌司他丁联合使用。希望临床能够对甲磺酸加贝酯的合理使用给予关注,以保障药物的有效性和安全性。Objective: To analyze the use of gabexate in inpatients and provide references for clinical rational use of drugs. Methods: All 115 cases of inpatients who used gabexate in our hospital from March 1,2017 to March 31,2017 were all selected. The data of inpatient’s gender,age,diagnosis,usage of drug and solvent,treatment course and drug combination were gathered and statistically analyzed by Excel(Microsoft 2011 edition).Furthermore,26 patients diagnosed with pancreatitis were selected and enrolled into groups. A preliminary study was conducted on the different dosage regimen of gabexate. Results: In 115 inpatients who used gabexate,the ratio of male to female was near to 1∶ 1,the patients of 40 ~ 60 years old were the major. The proportion of the patients without obvious medication indications accounted for 45. 22%,wrong solvent only accounted for 2. 61%,impropriety of solvent volume accounted for 74. 78%. The treatment course that met the recommendation of medicine specification accounted for 93. 91%. No matter single gabexate or drug combinations,or different treatment course(less than or more than 5 days),this therapeutic strategy did not make any difference for the laboratory tests,abdominal pain and hospitalization days of inpatients with pancreatitis. Conclusion: There is still some irrational clinical use of gabexate,the combination use of gabexate and ulinastatin is not recommended without sufficient evidence-basedmedical evidence. The clinical rational use of gabexate should be paid more attention in order to ensure the efficacy and safety of gabexate.

关 键 词：甲磺酸加贝酯 临床应用 合理性评价 用药点评 

分 类 号：R969.3[医药卫生—药理学]